Auris Medical Ag

Institut National De La Sante Et De La Recherche Medicale

Societe De Conseils De Recherches Et D'applications Scientifiques

Universitè De Montpellier

Jing Wang

Jean-Luc Puel

Remy Pujol

Matthieu Guitton

Jerome Ruel

Serge Auvin

Bernadette Pignol

Pierre-Entienne Chabrier De Lassauniere

Julien Menardo

Nesrine Benkafadar

The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.

Methods for the treatment of tinnitus induced by cochlear excitotoxicity

The invention concerns the use of a phenothiazine derivative of formula (I), wherein: R represents the hydrogen atom, an alkyl radical, arylalkyl, or &#x2014;C(O)R', for preparing a medicine for preventing and/or treating hearing loss. 

Use of a phenothiazine derivative for preventing and/or treating hearing loss

Growing community of inventors

Lunel, France

Jing Wang